Dergiler / Marmara Medical Journal / 2022 / Cilt: 35 - Sayı: 2

Which radiotherapy technique is better for neoadjuvant treatment of rectal cancer: A dosimetric comparison

Sayfa
181–186
Yayın Tarihi
2022-05-30
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Although, VMAT was the best method to decrease ID, HT produced better bladder sparing.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Our aim was to compare helical tomotherapy (HT) and volumetric modulated arc therapy (VMAT) plans with 3-dimensional conformal radiotherapy (3D-CRT) considering the planning target volume (PTV) and organs at risk (OARs) in rectal cancer patients treated with neoadjuvant radiotherapy.
📊
Temel Bulgular & Veri:Patients and Methods: Thirty patients, previously treated with intensity modulated radiotherapy (IMRT) or 3D-CRT from January 2014 to February 2020 were selected and 3 plans were generated for each patient using VMAT, HT and 3D-CRT.
💡
Sonuç & Katkı:Although, VMAT was the best method to decrease ID, HT produced better bladder sparing.
🔬Tür:Araştırma Makalesi
📍Kapsam:2014 Verileri
⚙️Değişkenler:Rectum cancer · Volumetric modulated arc therapy · Helical tomotherapy

Abstract

Objective: Our aim was to compare helical tomotherapy (HT) and volumetric modulated arc therapy (VMAT) plans with 3-dimensional conformal radiotherapy (3D-CRT) considering the planning target volume (PTV) and organs at risk (OARs) in rectal cancer patients treated with neoadjuvant radiotherapy. Patients and Methods: Thirty patients, previously treated with intensity modulated radiotherapy (IMRT) or 3D-CRT from January 2014 to February 2020 were selected and 3 plans were generated for each patient using VMAT, HT and 3D-CRT. Dosimetric comparisons were made for each plan regarding PTV and OARs. Integral dose (ID) was calculated and beam on times were analyzed. Results: The homogeneity index (HI) was significantly better in HT plans compared with VMAT and 3D-CRT plans (p<0.001), conformity index (CI) was better in VMAT plans. For small bowel, high doses were higher in 3D-CRT plans (p <0.001). HT produced lower doses for the bladder as compared to VMAT and 3D-CRT (p<0.005). The mean and maximum doses of bilateral femoral heads were higher in 3D-CRT plans. Beam on times were longer and IDs were higher in HT plans (p<0.001). Conclusion: Both VMAT and HT improved target homogeneity and conformity and decreased OAR doses compared to 3D-CRT. Although, VMAT was the best method to decrease ID, HT produced better bladder sparing.

🔖

Bu Makaleye Atıf Yap

KEFELI, A. U., KARABEY, A. U., DOKURLAR, U. E., TIRPANCI, B., OZKAN, G., KONUK, A. O., AKSU, M. G. (2022). Which radiotherapy technique is better for neoadjuvant treatment of rectal cancer: A dosimetric comparison. Marmara Medical Journal, Cilt: 35 - Sayı: 2, 181–186. https://ajindex.com/articles/688256

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49. doi: 10.3322/caac.21660
  2. Sauer R, Sauer R, Liersch T, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004. 351: 1731-40. doi: 10.1056/NEJMoa040694
  3. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355:1114-23. doi: 10.1056/NEJMoa060829
  4. Zorcolo L, Rosman AS, Restivo A, et al. Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis. Ann Surg Oncol 2012. 19:2822-32. doi: 10.1245/s10434.011.2209-y
  5. Clifford R, Govindarajah N, Parsons JL, Gollins S, West NP, Vimalachandran D. Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer. Br J Surg 2018;105:1553-72. doi: 10.1002/ bjs.10993
  6. Burbach JP, den Harder AM, Intven M, van Vulpen M, Verkooijen HM, Reerink O. Impact of radiotherapy boost on pathological complete response in patients with locally advanced rectal cancer: a systematic review and metaanalysis. Radiother Oncol 2014; 113:1-9. doi: 10.1016/j.radonc.2014.08.035
  7. Valentini V, Gambacorta MA, Cellini F, et al. The INTERACT Trial: Long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal)-cT3 rectal cancer. Radiother Oncol 2019;134:110-8. doi: 10.1016/j. radonc.2018.11.023
  8. Baglan KL, Frazier RC, Yan D, Huang RR, Martinez AA, Robertson JM. The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2002;52:176-83. doi: 10.1016/s0360-3016(01)01820-x
  9. International Commission on Radiation Units and Measurements. ICRU Report 62. Prescribing, recording, and reporting photon beam therapy (Supplement to ICRU Report 50). Bethesda, MD: ICRU, 1999:1-20
  10. Theodore S Hong, Jennifer Moughan, Michael C Garofalo, et al. NRG Oncology Radiation Therapy Oncology Group 0822: A Phase 2 Study of Preoperative Chemoradiation Therapy Using Intensity Modulated Radiation Therapy in Combination With Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys 2015